Can regorafenib effectively shrink solid tumors?

Regorafenib is an oral multi-target tyrosine kinase inhibitor that mainly achieves anti-tumor effects by inhibiting multiple targets related to tumor growth, angiogenesis and metastasis. The targets targeted by regorafenib include VEGFR, PDGFR, KIT, RAF, etc. These targets are closely related to the proliferation and angiogenesis of tumor cells. Through these mechanisms of action, regorafenib is widely used in the treatment of various solid tumors such as advanced colorectal cancer and liver cancer.

In clinical studies, regorafenib has indeed shown the potential to effectively reduce tumor size. Especially in the treatment of cancer types such as colorectal cancer (CRC) and hepatocellular carcinoma (HCC), regorafenib can not only delay the progression of the disease, but also reduce the size of the tumor. In multiple clinical trials, although the objective response rate (ORR) of regorafenib in patients with advanced colorectal cancer is not high, the median progression-free survival (PFS) is significantly prolonged, and some patients can achieve a reduction in tumor volume during treatment.

Although regorafenib is effective in controlling tumor growth, its effect on tumor size reduction varies among patients. In some patients, regorafenib can achieve significant tumor shrinkage and maintain a certain treatment response time; while in other patients, although the tumor volume shrinkage is not significant, the disease can still be controlled and the quality of life has been improved. This indicates that the efficacy of regorafenib is not entirely dependent on significant reduction in tumor volume, but rather extends patient survival by controlling tumor growth and metastasis.

Generally speaking, regorafenib can indeed effectively reduce tumor volume in some patients with advanced tumors, especially in advanced patients with colorectal cancer and liver cancer, showing significant efficacy. Although tumor volume reduction is not the only treatment indicator, through comprehensive inhibition of multiple targets, regorafenib can effectively delay tumor progression and improve patients' quality of life.

Reference materials:https://www.stivarga-us.com/